Historic Milestones

2011

December 2011

Acquired the U.S. marketing and distribution rights for Lanoxin®, Lanoxin® IV Parnate®, Zantac®, Fortaz® and Zinacef® from GlaxoSmithKline.

2012

January 2012

Initiated development of alternative dosage strengths of Lanoxin®.

October 2012

Entered into authorized generic agreement with Rising Pharmaceuticals for Parnate®.

2013

April 2013

Acquired the U.S. marketing and distribution rights for Kayexalate®, Nilandron®, Plaquenil®, Rilutek®, and Uroxatral® from Sanofi.

June 2013

Entered into authorized generic agreement with Rising Pharmaceuticals for Rilutek®.

October 2013

Received FDA approval for the alternative dosage strengths of Lanoxin®.

December 2013

Entered into authorized generic agreement with Par Pharmaceuticals for Lanoxin®.

2014

January 2014

Initiated funding of cardiology sales force for U.S. distribution partner to promote Lanoxin®.

February 2014

Acquired the U.S. marketing and distribution rights for DuToprol®.

October 2014

Acquired the U.S. marketing and distribution rights for Dibenzyline® and Dyrenium®.

Entered into authorized generic agreement with Prasco for several brands.

2015

January 2015

Acquired the U.S. marketing and distribution rights for Betapace® & Betapace AF®.

April 2015

Divested majority of product assets to Concordia Healthcare Corp in a deal valued at $1.2 billion.

May 2015

Acquired the U.S. marketing and distribution rights for Altoprev®.

2016

November 2016

Acquired the U.S. marketing and distribution rights for Sular®.

2017

April 2017

Acquired the U.S. marketing and distribution rights for Prilosec® Packets.

July 2017

Acquired the U.S. marketing and distribution rights for Alvesco®, Omnaris®, and Zetonna®.